Literature DB >> 24681298

Evolution of acquired resistance to anti-cancer therapy.

Jasmine Foo1, Franziska Michor2.   

Abstract

Acquired drug resistance is a major limitation for the successful treatment of cancer. Resistance can emerge due to a variety of reasons including host environmental factors as well as genetic or epigenetic alterations in the cancer cells. Evolutionary theory has contributed to the understanding of the dynamics of resistance mutations in a cancer cell population, the risk of resistance pre-existing before the initiation of therapy, the composition of drug cocktails necessary to prevent the emergence of resistance, and optimum drug administration schedules for patient populations at risk of evolving acquired resistance. Here we review recent advances towards elucidating the evolutionary dynamics of acquired drug resistance and outline how evolutionary thinking can contribute to outstanding questions in the field. Published by Elsevier Ltd.

Entities:  

Keywords:  Cancer; Drug resistance; Evolution; Mathematical modeling; Optimal dosing strategies

Mesh:

Substances:

Year:  2014        PMID: 24681298      PMCID: PMC4058397          DOI: 10.1016/j.jtbi.2014.02.025

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  97 in total

1.  An explicit representation of the Luria-Delbrück distribution.

Authors:  W P Angerer
Journal:  J Math Biol       Date:  2001-02       Impact factor: 2.259

2.  Evolution of resistance during clonal expansion.

Authors:  Yoh Iwasa; Martin A Nowak; Franziska Michor
Journal:  Genetics       Date:  2006-04       Impact factor: 4.562

3.  The fixed-size Luria-Delbruck model with a nonzero death rate.

Authors:  Natalia L Komarova; Lin Wu; Pierre Baldi
Journal:  Math Biosci       Date:  2007-05-03       Impact factor: 2.144

4.  The dynamics of gene amplification described as a multitype compartmental model and as a branching process.

Authors:  L E Harnevo; Z Agur
Journal:  Math Biosci       Date:  1991-02       Impact factor: 2.144

5.  Fluctuation analysis: the probability distribution of the number of mutants under different conditions.

Authors:  F M Stewart; D M Gordon; B R Levin
Journal:  Genetics       Date:  1990-01       Impact factor: 4.562

6.  Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.

Authors:  Juliann Chmielecki; Jasmine Foo; Geoffrey R Oxnard; Katherine Hutchinson; Kadoaki Ohashi; Romel Somwar; Lu Wang; Katherine R Amato; Maria Arcila; Martin L Sos; Nicholas D Socci; Agnes Viale; Elisa de Stanchina; Michelle S Ginsberg; Roman K Thomas; Mark G Kris; Akira Inoue; Marc Ladanyi; Vincent A Miller; Franziska Michor; William Pao
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

Review 7.  Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies.

Authors:  Robert A Gatenby; Thomas L Vincent
Journal:  Mol Cancer Ther       Date:  2003-09       Impact factor: 6.261

8.  Growth of nonnecrotic tumors in the presence and absence of inhibitors.

Authors:  H M Byrne; M A Chaplain
Journal:  Math Biosci       Date:  1995-12       Impact factor: 2.144

9.  Stochastic analysis of intermediate lesions in carcinogenesis experiments.

Authors:  E G Luebeck; S H Moolgavkar
Journal:  Risk Anal       Date:  1991-03       Impact factor: 4.000

10.  Effect of cellular quiescence on the success of targeted CML therapy.

Authors:  Natalia L Komarova; Dominik Wodarz
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

View more
  86 in total

Review 1.  Cell death in genome evolution.

Authors:  Xinchen Teng; J Marie Hardwick
Journal:  Semin Cell Dev Biol       Date:  2015-02-25       Impact factor: 7.727

Review 2.  The evolution of tumour phylogenetics: principles and practice.

Authors:  Russell Schwartz; Alejandro A Schäffer
Journal:  Nat Rev Genet       Date:  2017-02-13       Impact factor: 53.242

3.  Towards early monitoring of chemotherapy-induced drug resistance based on single cell metabolomics: Combining single-probe mass spectrometry with machine learning.

Authors:  Renmeng Liu; Mei Sun; Genwei Zhang; Yunpeng Lan; Zhibo Yang
Journal:  Anal Chim Acta       Date:  2019-09-25       Impact factor: 6.558

4.  Microenvironmental Niches and Sanctuaries: A Route to Acquired Resistance.

Authors:  Judith Pérez-Velázquez; Jana L Gevertz; Aleksandra Karolak; Katarzyna A Rejniak
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 5.  The Future of Combining Carbon-Ion Radiotherapy with Immunotherapy: Evidence and Progress in Mouse Models.

Authors:  Takashi Shimokawa; Liqiu Ma; Ken Ando; Katsutoshi Sato; Takashi Imai
Journal:  Int J Part Ther       Date:  2016-08-29

6.  4th international conference on tumor progression and therapeutic resistance: meeting report.

Authors:  Varun V Prabhu; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

7.  Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers.

Authors:  Ivana Bozic; Martin A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

8.  Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222.

Authors:  Dan-Dan Yu; Ying Wu; Xiao-Hui Zhang; Meng-Meng Lv; Wei-Xian Chen; Xiu Chen; Su-Jin Yang; Hongyu Shen; Shan-Liang Zhong; Jin-Hai Tang; Jian-Hua Zhao
Journal:  Tumour Biol       Date:  2015-10-02

Review 9.  Modeling Tumor Clonal Evolution for Drug Combinations Design.

Authors:  Boyang Zhao; Michael T Hemann; Douglas A Lauffenburger
Journal:  Trends Cancer       Date:  2016-03

Review 10.  The mathematics of cancer: integrating quantitative models.

Authors:  Philipp M Altrock; Lin L Liu; Franziska Michor
Journal:  Nat Rev Cancer       Date:  2015-12       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.